Clinical Trial Update: Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating ibrutinib in patients with relapsed or refractory follicular lymphoma. Results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-04-26